国内首个获批应用的BNCT治疗中心在琼试运营，中生科服迎来估值重塑

Core Insights - China has officially launched the trial operation of Pengbo Hospital, making it the second country globally to have a clinically approved Boron Neutron Capture Therapy (BNCT) treatment facility, marking a significant breakthrough in advanced cancer precision radiotherapy [1][3] Group 1: Hospital Launch and Operations - Pengbo Hospital, a wholly-owned subsidiary of China Biotech Services, aims to establish an integrated diagnosis and treatment service network to promote the application of BNCT technology nationwide [1] - The hospital has formed strategic partnerships with several institutions to enhance imaging technology support, explore combined treatments, develop inclusive medical insurance, and establish a collaborative treatment network [1] Group 2: Market Potential and Demand - As the only approved BNCT clinical treatment facility in China, Pengbo Hospital is expected to become a core growth driver for the company by 2026, driven by both policy support and market demand [2][3] - The potential demand for BNCT centers in major cities across China is estimated to be no less than 700 units, indicating a vast market opportunity [3] Group 3: Treatment Efficacy and Applications - BNCT is recognized for its precision targeting, minimal side effects, and repeatability, with international clinical data showing over 80% one-year survival rates for patients with advanced or recurrent head and neck cancers [3] - The hospital's approved indications include various types of inoperable locally advanced or recurrent head and neck cancers, with ongoing clinical research expanding to other solid tumors such as breast cancer and glioblastoma [3] Group 4: Financial Outlook and Growth - The hospital's initial capacity is approximately 40 beds, with an expected annual patient reception capacity of 1,500 to 2,500, potentially generating annual revenues of 700 million to 1.2 billion yuan based on treatment costs [5] - The continuous approval of new indications is anticipated to provide new revenue growth points for the company, contributing to a transformation of its main business and a potential revaluation of the company's stock [4][5]